Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins

29 Feb 2016

Abstract excerpt

Multiple myeloma arises when malignant plasma cells invade and form multiple tumors in the bone marrow. High levels of heparanase (HPSE) correlate with poor prognosis in myeloma patients. A likely target of the enzyme is the heparan sulfate (HS) proteoglycan syndecan-1 (Sdc1, CD138), which is highly expressed on myeloma cells and contributes to poor prognosis in this disease. We find that HPSE promotes an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to Cellular Mechanics and Interactions
Share to Proteoglycans and glycosaminoglycans research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26926788
DOI: 10.1038/oncsis.2016.5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatinsPMID 26926788Read ↗

Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells.Semantic proximity Read ↗

Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.Semantic proximity Read ↗

Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.Semantic proximity Read ↗

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaSemantic proximity Read ↗

Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.Semantic proximity Read ↗

Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.Semantic proximity Read ↗

MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting HeparanaseSemantic proximity Read ↗

Syndecan-1 (CD138), Carcinomas and EMTSemantic proximity Read ↗

Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple MyelomaSemantic proximity Read ↗

The Role of the Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 In Breast Cancer PathophysiologySemantic proximity Read ↗

SULFs in human neoplasia: implication as progression and prognosis factorsSemantic proximity Read ↗

Versican Proteolysis Predicts Immune Effector Infiltration and Post-Transplant Survival in MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.